Phreesia, Inc. (NYSE:PHR – Get Free Report) COO Evan Roberts sold 10,716 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $27.48, for a total value of $294,475.68. Following the completion of the sale, the chief operating officer now directly owns 764,307 shares of the company’s stock, valued at $21,003,156.36. The trade was a 1.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Evan Roberts also recently made the following trade(s):
- On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total value of $348,175.19.
- On Wednesday, January 15th, Evan Roberts sold 1,785 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total value of $48,159.30.
- On Wednesday, January 8th, Evan Roberts sold 2,681 shares of Phreesia stock. The shares were sold at an average price of $27.95, for a total value of $74,933.95.
- On Monday, January 6th, Evan Roberts sold 2,873 shares of Phreesia stock. The shares were sold at an average price of $26.61, for a total value of $76,450.53.
Phreesia Trading Down 1.8 %
Shares of NYSE PHR opened at $28.47 on Friday. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -19.37 and a beta of 0.94. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $29.90. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The stock’s 50 day simple moving average is $24.98 and its 200 day simple moving average is $23.28.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on PHR shares. Robert W. Baird lowered their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. KeyCorp increased their target price on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a report on Wednesday, January 8th. Piper Sandler reaffirmed an “overweight” rating and set a $33.00 target price (up previously from $31.00) on shares of Phreesia in a report on Wednesday. Finally, Royal Bank of Canada raised Phreesia from a “sector perform” rating to an “outperform” rating and increased their target price for the stock from $24.00 to $32.00 in a report on Wednesday, January 8th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $31.15.
Read Our Latest Stock Analysis on PHR
Institutional Trading of Phreesia
Hedge funds have recently added to or reduced their stakes in the business. R Squared Ltd bought a new stake in Phreesia during the 4th quarter valued at $30,000. International Assets Investment Management LLC raised its stake in Phreesia by 2,179.7% during the 3rd quarter. International Assets Investment Management LLC now owns 1,459 shares of the company’s stock valued at $33,000 after acquiring an additional 1,395 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in Phreesia during the 4th quarter valued at $76,000. XTX Topco Ltd bought a new stake in Phreesia during the 3rd quarter valued at $247,000. Finally, Hsbc Holdings PLC bought a new stake in Phreesia during the 2nd quarter valued at $301,000. Institutional investors own 92.10% of the company’s stock.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- What Are the U.K. Market Holidays? How to Invest and Trade
- Nebius Group: Market Overreaction or Real AI Disruption?
- What is a Stock Market Index and How Do You Use Them?
- The Best Way to Invest in Gold Is…
- What is the MACD Indicator and How to Use it in Your Trading
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.